BON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing

Rhea-AI Summary

BON (Nasdaq: BON) inaugurated the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing on December 18, 2025 in Xi'an, China. The lab pairs BON's Xi'an App-Chem subsidiary with Shaanxi Chang'an Pilot to develop fermentation-based, AI-optimized bio-manufactured natural actives.

The Joint Laboratory will target functional food and personal care ingredients, aiming to improve production efficiency, supply reliability, and environmental sustainability versus traditional plant extraction methods.

Positive

• Joint Laboratory inaugurated on December 18, 2025
• Focus on fermentation biosynthesis and AI process optimization
• Targets improved production efficiency, supply reliability, sustainability

Negative

• None.

News Market Reaction

-0.61%

1 alert

-0.61% News Effect

On the day this news was published, BON declined 0.61%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Joint lab inauguration date: December 18, 2025 BON founding year: 2006 Chang’an Pilot founding year: 2022 +5 more

8 metrics

Joint lab inauguration date December 18, 2025 Launch of BON & Chang'an Pilot joint laboratory

BON founding year 2006 Year BON was founded

Chang’an Pilot founding year 2022 Year Chang’an Pilot was established

Current share price $1.64 Pre-news price on publication date

52-week high $73.75 Pre-news 52-week high level

52-week low $1.14 Pre-news 52-week low level

Registered shelf size $500,000,000 Maximum amount under amended F-3 shelf registration

2025 revenue $18,670,684 Revenue for year ended September 30, 2025 (20-F)

Market Reality Check

Price: $1.65 Vol: Volume 24,045 is near its...

normal vol

$1.65 Last Close

Volume Volume 24,045 is near its 20-day average of 22,956, suggesting limited pre-news repositioning. normal

Technical Shares at $1.64 are trading slightly below the $1.66 200-day moving average.

Peers on Argus

Sector peers show mixed moves, with names like CNEY up 4.16% and BGLC up 5.42%, ...

1 Up

Sector peers show mixed moves, with names like CNEY up 4.16% and BGLC up 5.42%, while BSLK is slightly down 0.05%. BON’s price was unchanged pre‑headline, pointing to a stock-specific catalyst rather than a broad sector trend.

Historical Context

4 past events · Latest: Dec 10 (Positive)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Dec 10	Sales agreement	Positive	+8.2%	Kombucha-inspired product and $12M strategic sales deal in Greater China.
Nov 25	Sales agreement	Positive	+0.6%	$26M, 36‑month cooperation for second‑gen tea pigment digestive products.
Sep 09	Sales agreement	Positive	+24.7%	$18M, 24‑month deal for second‑gen Apple Series health products.
Sep 02	R&D breakthrough	Positive	+5.0%	AI-powered identification of promising weight‑managing tea compounds.

Pattern Detected

Recent commercial and product announcements have generally coincided with positive one-day price reactions.

Recent Company History

Over the last six months, BON emphasized commercialization deals around functional ingredients. Agreements with Beijing Huahai Keyuan and Qingshengyuan carried guaranteed or stated values of $18M, $26M, and a $12M sales pact, plus an AI-driven weight-management discovery update. These news items produced one-day gains ranging from about flat to nearly 25%. Today’s joint laboratory partnership continues the strategy of leveraging R&D and partnerships across functional foods and personal care.

Regulatory & Risk Context

Active S-3 Shelf · $500,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-07

$500,000,000 registered capacity

An amended Form F-3 shelf dated 2025-11-07 registers up to $500,000,000 of securities for potential future offerings. The shelf was not yet effective as of the latest data and shows 0 recorded usages, so any capital-raising under this program would depend on future effectiveness and market conditions.

Market Pulse Summary

This announcement highlights BON’s push to strengthen its technology backbone via a joint laboratory...

Analysis

This announcement highlights BON’s push to strengthen its technology backbone via a joint laboratory with Chang’an Pilot, emphasizing fermentation-based biosynthesis and AI-enabled process optimization for natural ingredients. It complements prior commercialization agreements in functional foods and personal care. At the same time, recent filings show revenue of $18,670,684, a net loss, and an amended F-3 shelf for up to $500,000,000 in securities. Investors may track future contracts, margin trends, and any usage of the shelf registration to gauge impact.

Key Terms

bio-manufacturing, biosynthesis, fermentation-based biosynthesis, artificial intelligence-enabled process optimization

4 terms

bio-manufacturing technical

"BON possesses technical capabilities in natural ingredient extraction, separation, and biosynthesis, supported by a proprietary artificial intelligence-enabled bio-manufacturing research"

Bio-manufacturing is the large-scale production of medicines and medical ingredients using living cells, microbes, or biological systems in specialized factories, along with the equipment and processes that keep them safe and consistent. Investors care because a company’s ability to reliably make complex biological products — at the right scale, cost and quality and under strict regulatory oversight — determines whether a treatment can reach patients, generate revenue and sustain competitive advantage; think of it as the factory and quality control that turn a scientific breakthrough into a sellable product.

biosynthesis medical

"Through the integration of fermentation-based biosynthesis, natural compound isolation, and artificial intelligence-enabled process optimization"

Biosynthesis is the natural process cells use to build complex molecules from simpler building blocks, like a microscopic factory assembling parts into finished products such as proteins, fats or small drug-like compounds. For investors, biosynthesis matters because how efficiently and reliably a company can make a desired molecule affects production cost, scalability, regulatory risk and competitive advantage—similar to how a better assembly line lowers manufacturing costs and boosts output.

fermentation-based biosynthesis medical

"Through the integration of fermentation-based biosynthesis, natural compound isolation, and artificial intelligence-enabled process optimization"

Fermentation-based biosynthesis uses living microbes or isolated enzymes in controlled tanks to convert simple feedstocks (like sugars) into target molecules such as drugs, ingredients, or industrial chemicals. For investors it matters because this approach can lower production costs, reduce reliance on scarce raw materials, and enable scalable, sustainable manufacture of novel products—factors that can affect margins, capital needs, and competitive positioning.

artificial intelligence-enabled process optimization technical

"and artificial intelligence-enabled process optimization, the Joint Laboratory is intended to support the Company's efforts"

Use of computer systems that learn from data to make business operations run faster, cheaper, and with fewer mistakes. Like a smart thermostat that adjusts heating by learning patterns, this approach improves scheduling, quality control, equipment upkeep and supply flows so companies use less labor and materials while producing more reliably. Investors watch it because it can boost profits, reduce unexpected costs, and create a measurable competitive edge.

AI-generated analysis. Not financial advice.

XI'AN, China, Feb. 17, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON"or the "Company"), a leading bio-ingredient provider for the natural health and personal care industries, today announced the establishment of the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing (the "Joint Laboratory"). The Joint Laboratory was inaugurated on December 18, 2025 through a collaboration between the Company's domestic operating subsidiary, Xi'an App-Chem Bio-Tech Co., Ltd., and Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd. ("Chang'an Pilot").

The Joint Laboratory will focus on the research and development of bio-manufactured natural active ingredients for use in functional foods and personal care products. Through the integration of fermentation-based biosynthesis, natural compound isolation, and artificial intelligence-enabled process optimization, the Joint Laboratory is intended to support the Company's efforts to improve production efficiency, supply reliability, and environmental sustainability compared to traditional plant-based extraction methods.

Founded in 2006, BON operates in the development, manufacturing, and commercialization of natural active ingredients for applications in health and personal care products. The Company's product portfolio includes plant-derived extracts, functional food ingredients, and personal care actives. BON serves customers in China, North America, the European Union, Japan, South Korea, and other international markets.

BON possesses technical capabilities in natural ingredient extraction, separation, and biosynthesis, supported by a proprietary artificial intelligence-enabled bio-manufacturing research and development platform designed to integrate data analytics and process engineering for scalable production.

Chang'an Pilot, established in 2022, provides laboratory infrastructure and research services focused on life sciences and artificial intelligence-enabled manufacturing technologies.

Yongwei Hu, Chairman of BON, stated, "We believe the establishment of this Joint Laboratory will strengthen our research capabilities and create meaningful collaboration between our respective teams. We expect this initiative will support our continued efforts to develop scalable, high-quality natural ingredients and advance our long-term growth strategy."

About Bon Natural Life Limited ("BON")

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com.

For more information, please contact:

Cindy Liu | IR
Email: bonnatural@appchem.cn

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

View original content:https://www.prnewswire.com/news-releases/bon-partners-with-changan-pilot-to-launch-world-class-joint-laboratory-for-natural-ingredient-bio-manufacturing-302688229.html

SOURCE Bon Natural Life Limited

FAQ

What did BON announce about the new joint laboratory (BON) on February 17, 2026?

BON announced the establishment of a joint laboratory inaugurated December 18, 2025 to develop bio-manufactured natural ingredients. According to the company, the lab combines fermentation, natural compound isolation, and AI-enabled process optimization for scalable production.

How will the BON & Pilot Joint Laboratory affect BON's production (BON)?

The lab is intended to improve production efficiency, supply reliability, and environmental sustainability. According to the company, integrating fermentation and AI aims to be more efficient and consistent than traditional plant extraction methods.

Which organizations are collaborating in the BON Joint Laboratory (BON)?

The collaboration pairs BON's domestic subsidiary Xi'an App-Chem with Shaanxi Chang'an Pilot. According to the company, Chang'an Pilot provides laboratory infrastructure and research services for life sciences and AI-enabled manufacturing.

What product areas will the BON Joint Laboratory focus on (BON)?

The Joint Laboratory will focus on bio-manufactured natural active ingredients for functional foods and personal care products. According to the company, efforts center on fermentation-based biosynthesis and natural compound isolation.

Does BON provide timelines or commercial terms for the joint laboratory (BON)?

The announcement gives an inauguration date but no commercial revenue timelines or contract values. According to the company, the initiative is intended to support long-term growth through scalable, high-quality ingredient development.